Feb 24, 2017 at 21:20 | Source: Moneycontrol.com
Faced with increasing regulatory scrutiny -- Indian drug makers working more closely then ever before on Friday said they have been investing on automation, simplifying and standardizing systems and working on building culture of compliance within their organizations -- as they dont want to be seen as outliers in terms of regulatory compliance.
Feb 23, 2017 at 21:27 | Source: Moneycontrol.com
Data reliability or data integrity are often linked to allegations of data falsification or manipulation, which are cited as main reasons by US FDA for pulling up Indian companies as part of its regulatory scrutiny.
Feb 23, 2017 at 21:10 | Source: PTI
As many as 634 drugs of variousstrengths produced by firms, including Cipla, Abbott,Astrazeneca and Dr Reddy's, are "suspected" to benon-compliant with ceiling prices as notified by NPPA.
Feb 23, 2017 at 19:37 | Source: CNBC-TV18
Cipla is now concentrating on specific areas for growth. In emerging markets, Brazil and China are its priority markets, where measured approach will be taken, Umang Vohra, Managing Director of the company.
Feb 23, 2017 at 13:39 | Source: Moneycontrol.com
Easing regulatory concerns and actions by the US Food and Drug Administration (FDA) will help the sector and improve investor sentiment, Deutsche Bank said in a report.
Feb 21, 2017 at 16:58 | Source: PTI
Pragmatic compulsory licensing policy is needed to enable India to look after health of its people as it cannot afford monopoly in healthcare with the challenges it faces, Cipla's Y K Hamied said.
Feb 20, 2017 at 10:36 | Source: CNBC-TV18
Even though the sector has been a rank underperformer in the past, Indian telecom stocks are very attractive from a three-year perspective, according to S Naren, Executive Director at Chief Investment Officer at ICICI Prudential.
Feb 20, 2017 at 09:15 | Source: Moneycontrol.com
TCS, HUL, GAIL, Wipro, Bharti Airtel, Idea Cellular, Kotak Mahindra Bank and HCL Technologies were early gainers while Maruti Suzuki, Tata Motors, HDFC Bank, ITC, Cipla, Tata Motors (DVR) and Eicher Motors were losers.
Feb 18, 2017 at 12:54 | Source: PTI
As per Cipla's co-exclusive agreement with SII, the former will market the vaccine for adults while the latter will market it for adults and children, a company statement said.
Feb 17, 2017 at 14:00 | Source: Moneycontrol.com
Sun Pharma, HDFC Bank, GAIL, ICICI Bank, Cipla and Tata Motors were top gainers while Infosys, Asian Paints, TCS, Hero Motocorp, Wipro, Bharti Infratel, Hindalco and Idea Cellular were under pressure.